The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.

Abstract excerpt

FLT3 mutations, generally associated with a poor prognosis, are found in approximately one-third of patients with acute myeloid leukemia (AML) and represent an attractive therapeutic target. FLT3 inhibitors undergoing clinical evaluation include first-generation relatively non-specific small molecules and second-generation compounds with higher potency and selectivity against mutant FLT3. Recently presented...

Topics

• Antineoplastic Agents
• Antineoplastic Combined Chemotherapy Protocols
• Clinical Trials as Topic
• Drug Discovery
• Drug Resistance, Neoplasm
• Humans